Medicine

FDA Finally Approved an Alzheimer’s Drug—But Everything Surrounding It Is Controversial

Save
FDA Finally Approved an Alzheimer’s Drug—But Everything Surrounding It Is Controversial
A vial and packaging for the drug Aduhelm is shown on June 7, 2021. Biogen via AP
Updated:
Analysis

Aduhelm is the brand name under which the Alzheimer’s drug Aducanumab is marketed. It is developed by the U.S. company Biogen. The drug is to be administered as an intra-venous infusion every four weeks.

Health 1+1 is the most authoritative Chinese medical and health information platform overseas. The program covers the latest on the coronavirus, prevention, treatment, scientific research and policy, as well as cancer, chronic illness, emotional and spiritual health, immunity, health insurance, and other aspects to provide people with reliable and considerate care and help.
Related Topics